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ABSTRACT
The syndemic of human immunodeficiency virus
(HIV)/tuberculosis (TB) co-infection has grown as a
result of the considerable sociogeographic overlaps
between the two epidemics. The situation is particu-
larly worrisome in countries with high or intermediate
TB burden against the background of a variable HIV
epidemic state. Early diagnosis of TB disease in anHIV-
infected person is paramount but suffers from lack of
sensitive and specific diagnostic tools. Enhanced
symptom screening is currently advocated, and the
wide application of affordable molecular diagnostics is
urgently needed. Treatment of TB/HIV co-infection
involves the concurrent use of standard antiretrovirals
and antimycobacterials during which harmful drug
interaction may occur. The pharmacokinetic interac-
tion between rifamycin and antiretrovirals is a case in
point, requiring dosage adjustment and preferential
use of rifabutin, if available. Early initiation of antiret-
roviral therapy is indicated, preferably at 2 weeks after
starting TB treatment for patients with a CD4 of <50
cells/mL. Development of TB-immune reconstitution
inflammatory syndrome (TB-IRIS) is however more
frequent with early antiretroviral therapy. The diagno-
sis of TB-IRIS is another clinical challenge, and cau-
tious use of corticosteroids is suggested to improve
clinical outcome. As a preventive measure against
active TB disease, the screening for latent TB infection
should be widely practiced, followed by at least 6–9
months of isoniazid treatment.To date tuberculin skin
test remains the only diagnostic tool in high TB burden
countries. The role of alternative tests, for example,
interferon-g release assay, would need to be better
defined for clinical application.
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Abbreviations: AIDS, acquired immune deficiency syndrome;
CXR, chest X-ray; HAART, highly active antiretroviral therapy;
HIV, human immunodeficiency virus; MDR-TB, multidrug-
resistant tuberculosis; MTB, Mycobacterium tuberculosis; PI,
protease inhibitor; TB, tuberculosis; TB-IRIS, TB-immune recon-
stitution inflammatory syndrome; TST, tuberculin skin test.
INTRODUCTION
Co-infection of Mycobacterium tuberculosis (MTB)
and human immunodeficiency virus (HIV) has been
described as a perfect example of a ‘syndemic’,1 a term
denoting the coexistence of two infections interacting
synergistically leading to excessive burden in the
society. HIV-infected individuals are, as a direct con-
sequence of virus-associated immune deficiency, vul-
nerable to tuberculosis (TB) disease. The situation is
fuelled by ongoing exposure to infectious TB cases
and continuing reactivation of latent TB infections.
Prevalent among one-third of the global population,
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TB epidemic is evolving in the setting of considerable
sociogeographical overlaps between the two infec-
tions. Theoretically, in the absence of non-human res-
ervoirs, effective treatment of either TB or HIV
infections should result in the reduction of transmis-
sion of the implicating microorganisms. Unfortu-
nately, public health control of TB/HIV co-infections
remains a distant goal despite the availability of effi-
cacious treatment for both conditions.
In this review, we examine the current situation of
TB/HIV co-infection and discuss the main challenges
in the clinical management of TB in HIV-infected
individuals. (Table 1) Two interrelated TB states are
considered: first, latent TB infection that is non-
infectious, and second, active disease, an infectious
clinical condition that has progressed from latent
infection. Besides Africa, special attention is directed
to the Asia-Pacific region, home to a sizable popula-
tion affected by HIV and TB.
DISEASE BURDEN OF TB/HIV
CO-INFECTIONS
The World Health Organization estimated that there
were 12 million prevalent cases of TB in 2011, the
latter translating into 170 per 100 000 population.2
There were 8.7 million incident cases in the same
year, 11% (1.3 million) of which co-infected with HIV,
against the background of a global HIV prevalence of
34 million.3Whereas over half (59%) of all incident TB
occurred in Asia in 2011, 79% of TB/HIV co-infections
were in Africa, where 69% of the prevalent global HIV
infections are located. Generally speaking, the
TB/HIV burden in a country varies with the epidemic-
ity of HIV in the locality. By Joint United Nations Pro-
gramme on HIV/AIDS/World Health Organization
classification, three epidemic states can be
differentiated—generalized, concentrated and low
level. The incidence rate ratio of TB in HIV-infected
Table 1 Challenges in the clinical management of tuberculosis in HIV infected persons in high and intermediate burden
countries
Major issues in TB/HIV
co-infection Updated standard of practice Unresolved issues
Latent TB
infection
Detection of latent TB
infection
• Yearly TST screening  Role of IGRA
 Definition of treatment responses
Effective treatment • INAH for 6 or 9 months (consider 36
months in TST+ in high burden
settings)
 Design of best treatment regimen(s)
TB disease Prompt detection • Enhanced symptom screening
(cough + other symptoms) and chest
radiograph as necessary
• Molecular testing with Xpert MTB/RIF
if available
• Urine testing (molecular and/or
antigen) to be considered if low CD4
(< 100 cells/mL), and sputum scarce
cases
 Optimization of screening algorithm
 Defining the role of point-of-care
diagnostics
 Low-cost alternatives to current
diagnostic tests
Interaction between PI
and rifamycin
(rifamcyin essential in
TB regimen)
• Avoid rifampicin but include rifabutin
in TB regimen if available
• Reduce rifabutin to 150 mg QD or
equivalent when boosted PI is used
• Dose lopinavir/ritonavir at
800 mg/200 mg bd when rifampicin is
used (Do not use atazanavir, darunavir,
tipranavir or indinavir with rifampicin)
 Optimization of rifabutin dosage and
TB regimens
Interaction between
NNRTI and rifampicin
• Avoid nevirapine
• Use standard dose for efavirenz
(600 mg)
• Beware of significant interaction with
etravirine
 Potential interaction with newer
antiretroviral compounds
Initiation of HAART • Initiate at 2 weeks if CD4 <50 cells/mL,
except for TB meningitis
• Can defer to 8 weeks If CD4 >50
cells/mL
 Risk differentiation for initiating
HAART
Treatment of TB-IRIS • Cautious use of corticosteroids  Defining role of steroids
HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IGRA, interferon-g release assay; INAH, isoniazid;
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TB, tuberculosis; TB-IRIS, TB-associated immune recon-
stitution inflammatory syndrome; TST, tuberculin skin test.
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compared with uninfected persons was 20.6 in places
with generalized epidemic, 26.7 in concentrated epi-
demics, and high at 36.7 in low-level epidemics.4
Figure 1 shows the distribution of incident TB/HIV
cases and the background prevalence of HIV infection
by country. The apparently ‘lower’ relative risk in
countries in generalizedHIV epidemic state was likely
the consequence of a higher background TB rates in
the same places.
The risk of TB in HIV-positive persons has been
extensively reviewed.5 Its reported association with
one’s immunological status, as reflected by CD4
count and advanced CDC stage (or acquired immune
deficiency syndrome (AIDS) stage), was confirmed in
studies in African and Asian countries including
Ethiopia,6 China7 and Cambodia.8 Other risk factors
include smoking, silicosis and recent contacts withTB
transmitters who may not be HIV-infected.5 Sociode-
mographic characteristics also play a role, as reflected
by a higher incidence in occupations with higher TB
prevalence, for example, miners, and immigrants
from higher prevalence countries, and people who
use drugs..9,10 Male gender was associated with
TB/HIV co-infection, reflecting the gender associa-
tion in TB generally.6 The genetic influences on
TB/HIV co-infection have been studied, but data on
the associations so far are inconclusive.11 TB
co-infection in people living with HIV in incarcerated
setting is a unique problem, as reported in US prison
populations ever since the 1980s.12 In Africa, as much
as half of HIV-positive inmates had TB disease.13 The
HIV prevalence in TB patients in custody was
reported to range from 26% in Tanzania to 73% in
Malawi before highly active antiretroviral therapy
(HAART) became available.14,15 In Asia Pacific, one
study fromThailand included 554HIV/TB co-infected
patients, of which 40% had ever been in jail and 28%
in prison.16 Using tuberculin skin test (TST), a Malay-
sian study gave a prevalence of 88.8% for latent TB
infection in a prison population (A Kamarulzaman,
2010, unpubl. data).
Worldwide,TB incidence has fallen since the turn of
the century.2 The pattern is more complex for TB/HIV
co-infection because of the changes and geographical
variation in the coverage of HIV testing and the evolv-
ing access to HAART. Studies in Taiwan and Brazil
reported a fourfold to eightfold reduction of TB inci-
dence in HIV patients following HAART.17,18 The
number of incident TB cases remained high within
the first 6 months after HAART initiation.6 Overall, it
was estimated that HAART could reduce the risk of TB
disease in people living with HIV by 65%.19 While TB
mortality in HIV negative people has fallen by 41%
since 1990,2 similar impacts would take longer time to
achieve among HIV-positive persons. The epidemiol-
ogy of multidrug-resistant TB in HIV patients is, like-
wise, variable.20 It was found to be disproportionately
higher than HIV-negative TB patients in some coun-
tries, including Ukraine, Botswana, Russia, Vietnam
and Argentina.20–22 With the use of a mathematical
Figure 1 Distribution of estimated cases of incident tuberculosis/human immunodeficiency virus (HIV) co-infections against the
background of estimated prevalence of HIV infection in selected high burden countries, in 2011. Data sources: references ‘Global Report:
UNAIDS Report on the Global AIDS Epidemic 2012’3 and Getahun et al.4
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model, it was demonstrated that HIV populations
were not at a higher risk of contracting multidrug-
resistant TB, although the prevalence of the latter
could increase with rising HIV in the population over
time.23 The conclusion echoed that of an earlier
review describing multidrug-resistant TB as a locally
severe problem, the spread of which could be control-
led by standard short-course chemotherapy.24
DIAGNOSING TB IN THE SETTING OF
HIV/AIDS
TB/HIV co-infection is characterized by a heteroge-
neous clinical course that varies with timing and
nature of TB disease (infection vs reactivation), CD4
counts, treatment access, and adherence to HAART.25
Overall, TB remains a common AIDS-defining illness,
and pulmonary presentation is common, in high and
intermediate TB burden countries. Compared with
patients on HAART and HIV-negative patients, non-
treated HIV patients have a higher tendency of
extrapulmonary manifestations, atypical chest X-ray
(CXR) with lower lobe involvements, miliary patterns
and hilar lymphadenopathy.25,26 A meta-analysis con-
cluded that extrapulmonary TB was associated with a
CD4 count <100 cells/mL.27 In Africa, significant
weight loss has continued to be a common feature of
TB/HIV disease. As recommended in the latestWorld
Health Organization guidelines, symptom screening
constitutes one important strategy for detecting TB in
people livingwithHIV.28 Emphasis has been placed on
the detection of cough of 2–3weeks followed by smear
for acid fast bacilli.29 While these strategies carry
merits, especially in resource poor settings, there are
the potential shortcomings of missing asymptomatic
but active disease. Studies have shown that smear-
negative cases accounted for 24–61% of TB/HIV
co-infections.30,31 Various forms of enhanced
symptom screening including the use of CXR and TB
culture have been pursued. In one study in South
Africa, sensitivity of symptom screening comprising
cough, appetite loss or night sweat of over 2 weeks
rose from 74.5% to 96.1% after including CXR.32
Routine CXR screening on its own however gave a low
yield of the detection of active TB disease in asymp-
tomatic HIV-infected patients even if the background
TB prevalence is high.33 CXR may be normal in HIV-
positive patients with sputum culture-confirmed TB.
Recently, a meta-analysis suggested absence of
current cough, fever, night sweat and weight loss as
the best performing screen to rule out TB in resource-
constrained setting.34 For extrapulmonary TB, a diag-
nosis depends on clinical suspicion, appropriate use
of clinical investigations (e.g. lymph node, cerebros-
pinal fluids), and reassessment following treatment
initiated in the absence of bacteriological evidence.29
Due to the limitations of sputum smear and CXR in
diagnosing pulmonary presentation in HIV patients
and because diagnostic delay is an important con-
tributor tomortality, improving diagnostic testing has
been a main priority for TB/HIV research. Introduced
recently, Xpert MTB/RIF assay (Cepheid, Sunnyvale,
CA, USA) is an automated nucleic acid amplification
test for detecting TB and rifampicin resistance (as a
surrogate of multidrug-resistant TB). Its sensitivity for
detectingTB inHIV co-infectionwas 84% (overall) but
lower at 61% in smear-negative cases in a South
African study.35 As the given sensitivities rely on single
samples, higher sensitivities may be obtained if serial
sampling is performed. Another study on intensive
screeningofHIV-positive individualswithoutTBdiag-
nosis reported an increase in case detection by 45%
compared with sputum smear microscopy alone.36
Urine screening with Xpert MTB/RIF assay offers an
alternative approach, which gave a higher sensitivity
in patients with CD4 <50/mL comparedwith those less
immunologically deficient and when combined with
sputum testing.37 Detection of urine or sputum
lipoarabinomannan, a lipopolysaccharide antigen,
has been investigated. Urine testing for lipoarabi-
nomannanplusXpertMTB/RIFassayhadacombined
sensitivity of 70%, which can be potentially useful as
HIV patients with TB are often ‘sputum-scarce’.38 The
availability of lipoarabinomannan strip test is making
point-of-care testing possible. In late December 2010,
World Health Organization endorsed the use of Xpert
MTB/RIF assay as anovel diagnostic test, although the
high cost is a cause for concern. In highTBburden and
HIV prevalence setting, the cost-effectiveness of Xpert
is comparable with culture in the management of
advanced HIV diseases initiating HAART.39 A model-
based analysis further suggested that routine screen-
ingof twoXpert samplesprior to initiationofHAART is
cost-effective.40
TB-ASSOCIATED IMMUNE
RECONSTITUTION INFLAMMATORY
SYNDROME
TB-associated immune reconstitution inflammatory
syndrome (TB-IRIS) is a paradoxical reaction charac-
terized by its occurrence during rapid recovery of
immune function after starting HAART. On antiretro-
viral therapy, there is precipitous reduction in HIV
viral load within the first weeks resulting in rapid, but
partial, improvement in pathogen-specific immune
responses that drive an inflammatory reaction
against MTB antigen. Unlike paradoxical reactions in
patients who are not on HAART,41 TB-IRIS is often
accompanied by features of systemic inflammation
and multisystem involvement. Pathogenic markers
associated with TB-IRIS include elevations of a broad
range of pro-inflammatory cytokines, most consist-
ently IL-6 (interleukin-6), TNF-a (tumour necrosis
factor-alpha), IFN-g (interferon-gamma) in one
study,42 increase in mycobacterial-specific T-cell
numbers and presence of innate immune cells at the
site of disease.43 Another form of TB-IRIS (unmasking
TB-IRIS) affects patients with unrecognized active TB
when started on HAART, which is characterized by
exaggerated inflammatory presentations in the first
weeks of antiretroviral therapy. The incidence of
unmaskingTB-IRIS depends onTB epidemiology and
effectiveness of baseline TB screening.
A meta-analysis of cohort studies concluded that
TB-IRIS occurs in 15.7% of TB/HIV patients starting
TB/HIV co-infection 915
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HAART.44 TB-IRIS symptom onset typically occurs
within the first 4 weeks of antiretroviral therapy. The
most frequent features are recurrenceofTB symptoms
such as cough, night sweats, fever, lymph node
enlargement and suppuration, new or enlarging
serous effusions, worsening of radiographic pulmo-
nary infiltrates, and formation of tuberculous
abscesses. Frequent features of systemic inflamma-
tion are tachycardia, weight loss and prominent con-
stitutional symptoms. TB-IRIS involving liver with
granulomatous hepatitis may result in liver function
abnormalities and jaundice.45 A wide range of CXR
patterns are seen including nodular infiltrates, con-
solidation, cavitation, and enlarging effusions or tho-
racic lymph nodes. The most life-threatening form of
TB-IRIS is central nervous system involvement result-
ing in meningitis or enlarging cerebral tuberculomas
or abscesses.43,46 Other potentially fatalmanifestations
include: accumulationofpericardial effusions causing
tamponade (Fig. 2), rapid splenic enlargement result-
ing in rupture, bilateral kidney involvement with
granulomatous inflammation leading to renal failure,
bronchial compression by enlarging lymphnodes and
intestinal perforation. Deaths due to paradoxical
TB-IRIS have been describedwith an overall mortality
of 3.2% in a meta-analysis.44 In cohort studies of
patients started onHAART, however, the development
of TB-IRIS did not significantly increase the risk of
death likely because TB-IRIS typically affects those
with a substantial underlyingmortality risk in relation
with their baseline advanced stage.47
Major risk factors for TB-IRIS are a low CD4 count
and short interval between starting TB treatment and
HAART. The median duration of TB-IRIS symptoms is
2–3 months,48 but its duration and severity may be
very variable,49 with a small proportion experiencing
symptoms for much longer, as a result of refractory
pus collections. Cases lasting longer than a year are
described, and late relapses have been reported.49,50
Long-term outcomes are favourable.49 In the absence
of confirmatory diagnostic test, diagnosis of TB-IRIS
is based on the characteristic clinical features occur-
ring soon after HAART, and exclusion of relevant
differential diagnoses, particularly alternative oppor-
tunistic infections and drug-resistant TB.Where diag-
nostic resources are limited, drug susceptibility
testing is unavailable, or when the initial TB diagnosis
has not been microbiologically confirmed, the diag-
nosis can be particularly challenging. International
consensus on case definitions have been established
to standardize the diagnostic criteria for research
reports.51 These have been validated in several studies
and can be used clinically for making the diagnosis.
As regards to the treatment of TB-IRIS, corticoster-
oid use has been associated with risks of herpes reac-
tivations, strongyloides hyperinfection and other
infections. In a randomized, controlled trial
(n = 110),52 a 4-week course of prednisone at 1.5 mg/
kg/day for 2 weeks followed by 0.75 mg/kg/day for 2
weeks gave a significant reduction in the combined
primaryend-pointofnumberofdayshospitalizedand
outpatient therapeutic procedures compared with
placebo. There was also more rapid improvement in
symptoms, quality of life score, CXR and reduction in
C-reactive protein, with no excess of severe infections
or metabolic side-effects. In another observational
study, corticosteroid for a median of 68 days was well
tolerated and was associated with one case of zoster.49
A subgroup of patients responding to corticosteroids
suffered from relapse on stopping, requiring longer
durations of treatment.49,52 While corticosteroids may
reduce health-care utilization and improve symp-
toms, this should be deferred when the TB-IRIS diag-
nosis is not certain, pending further diagnostic work-
up. Non-steroidal anti-inflammatory drugs have also
beenused to treatTB-IRIS.Theuseof specific cytokine
blocking therapies (such as TNF-a blockers) has been
suggested, but this remains experimental. Aspiration
of pus collections can result in symptomatic relief and
provide a sample to exclude infection with drug-
resistantTB.48TB-IRIS is not an indication for stopping
HAART,unless there is centralnervous systeminvolve-
(a) (b)
Figure 2 This human immunodefi-
ciency virus (HIV)-infectedman had a
CD4 count of 113 cells/mL and was
diagnosedwith pulmonary and nodal
tuberculosis (TB). He started highly
active antiretroviral therapy (HAART)
4 weeks after TB treatment. Three
weeks after starting HAART he had
recurrence of TB symptoms attrib-
uted to TB-immune reconstitution
inflammatory syndrome. His chest
X-ray taken at this time (b)when com-
pared with his pre- antiretroviral
therapy one (a) showed enlargement
of mediastinal lymphadenopathy,
worsening pulmonary infiltrate and
massive enlargement of the cardiac
shadow due to a pericardial effusion.
He required urgent pericardiocente-
sis (1.5 L drained) and was treated
with prednisone for 7 weeks with
resolution of symptomsandno recur-
rence of the effusion.
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mentwith depressed level of consciousness. Unmask-
ing TB-IRIS is less well defined and studied, the
management of which involves prompt TB diagnosis
and initiation ofTB treatment.There is no prospective
evidence for corticosteroids in unmasking TB-IRIS.
WHEN TO START ANTIRETROVIRAL
THERAPY IN HIV-INFECTED
TB PATIENTS
Treatment of TB/HIV co-infection involves the
timely use of HAART and anti-TB treatment. There
are concurrent risks to consider when deciding on
the optimal time to initiate HAART in TB co-infected
HIV patients who are not yet on antiretroviral
therapy. The most important of these are the risk of
death secondary to opportunistic infections related
to delaying HAART and the risk of death from severe
TB-IRIS associated with earlier HAART. Both risks are
highest in patients with the lowest CD4 counts. Until
recently, guidance on the optimal time to start
HAART in patients with TB was founded on observa-
tional data and expert opinions. In 2011, three ran-
domized, controlled strategy trials on optimal
HAART timing in TB patients were published that
have considerably strengthened the evidence base
for guidelines on this issue. One further trial has
been published in 2012.
The CAMELIA (CAMbodian Early vs Late Introduc-
tion of ART) trial in Cambodia involved 661 HIV-
infected TB patients with very advanced disease
(medianCD4count25cells/mLandmedianbodymass
index 17) randomized to commence HAART at 2 or 8
weeks after starting TB treatment. Mortality was sig-
nificantly reduced in those who received earlier
HAART(18%vs27%,hazard ratio0.62, 95%confidence
interval 0.44–0.86).53 The STRIDE (Immediate Versus
Deferred Start of Anti-HIV Therapy in HIV-Infected
Adults Being Treated for Tuberculosis) trial, a multi-
center study, enrolled 809 patients with HIV-
associated TB who had a CD4 count <250 cells/mL to
commenceHAARTwithin 2weeks of startingTB treat-
ment or after 8–12 weeks. Whereas the primary end-
point (deathornewAIDS-defining illnessby 48weeks)
did not differ between the two arms, it was less fre-
quent in those with a CD4 count at initiation of <50
cells/mL (15.5% vs 26.6%, P = 0.02).54 The SAPiT
(Staring ART at 3 Points in TB) trial (n = 642) was con-
ducted in South Africa and enrolled ambulatory HIV-
infected patients with smear-positive pulmonary
presentation and CD4 count <500 cells/mL.55 Patients
were randomized to one of three arms for initiating
HAART: within 4 weeks of starting TB treatment,
within 4 weeks of completing intensive phase of TB
treatment, and within 4 weeks of completing the full
course of TB treatment. Participants had a median
CD4 of 150 cells/mL. The arm that involved waiting
until TB treatment completion was stopped early by
the Data Safety and Monitoring Board because of
excess mortality.56 There was no significant difference
between the remaining two arms in terms of the
primary end-point (again death or newAIDS-defining
illness). However, when analysis was restricted to
those with CD4 <50 cells/mL, there was a reduction in
the incidence of this combined outcome in those who
started within 4 weeks of starting TB treatment with
borderline statistical significance (8.5 vs 26.3 cases per
100 person years, P = 0.06). TB-IRIS and adverse
events requiring antiretroviral regimen switch were
more frequent in the early arm. The more recently
published TIME (Appropriate Timing of HAART in
Co-infected HIV/TB Patients) study conducted in
Thailand57 comparedstartingHAARTat4weeksversus
12weeks inTBpatientswithCD4 counts <350 cells/mL
with 1 year all-cause mortality as the primary
outcome. The investigators enrolled 156 participants,
mostly with advanced immunosuppression (median
CD4count = 43 cells/mL). EarlierHAARTwasnot asso-
ciated with a survival advantage, with an overall mor-
tality of 7% without difference between the two arms.
Possible reasons for the different results in this trial
versus the previous three could be the smaller sample
size and/or differences in the characteristics of the
participants that were independent of CD4 count.
Taken together, these clinical trial findings (with
the exception of the TIME study) suggest that the
patients with CD4 <50 cells/mL would benefit most
from early HAART initiation (within 2 weeks of TB
treatment). In patients with higher CD4 counts, it
may be appropriate to defer HAART until around 8
weeks on TB treatment to reduce a roughly twofold
increased risk of TB-IRIS. For programmatic simplic-
ity, some clinical services may decide to start all
patients at 2 weeks, and this certainly seems appro-
priate in patients with clinically advanced HIV
disease even if the CD4 count is >50 cells/mL.55 TB
meningitis is a special issue that was addressed in a
randomized, controlled trial in Vietnam.58 Compari-
son was made between immediate HAART versus
initiation at 2 months after starting TB treatment for
TB meningitis in 253 HIV patients. Mortality by 9
months was very high (~60%) but did not differ by
study arm, although there were significantly more
grade 4 adverse events in the early arm. All partici-
pants had received high-dose adjunctive dexametha-
sone, which may have resulted in fewer cases of
severe TB-IRIS related to early HAART. Because
TB-IRIS involving the central nervous system carries
higher mortality risk.43,46 it could be hypothesized
that early HAART for TB meningitis can be harmful.
In settings where adjunctive corticosteroids are not
used for TB meningitis, early HAART may be more
harmful, but this has not been assessed.
DRUG CO-TOXICITIES AND
INTERACTIONS
Shared toxicity and harmful drug interactions
between antiretrovirals and anti-TB medications
create a major challenge in managing HIV/TB
co-infection. (Table 2) In addition, rifampicin results
in potent induction of many genes involved in the
metabolism and transport of other drugs. These
include genes encoding cytochromeP450 isoenzymes
(particularly 3A4/5) and the drug transporter
p-glycoprotein that are key in the metabolism and
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transport of non-nucleoside reverse transcriptase
inhibitor and protease inhibitors (PI) classes of drugs.
Co-administration of rifampicin-based TB treatment
may result in subtherapeutic concentrations of non-
nucleoside reverse transcriptase inhibitors and PI,
potentially causing development of treatment failure
and antiretroviral resistance.59 There are no signifi-
cant interactions between rifampicin and the NRTI
class. Interactions with other classes of antiretroviral
drugs are discussed later.
Non-nucleoside reverse transcriptase inhibitor
and rifampicin
As a commonly used non-nucleoside reverse tran-
scriptase inhibitor, the interaction between nevirap-
ine is of particular concern. In the presence of
rifampicin treatment, the level of nevirapine is
reduced, especially during the initial 2-week lead-in
period with a lower dosage of 200 mg daily.60,61 A large
cohort study conducted in South Africa62 demon-
strated that virological suppression rate was worse in
patients on nevirapine-based HAART who received
concomitant rifampicin-based TB treatment. One
strategy that has been suggested is to omit the nevi-
rapine lead-in dose when there is no alternative to
nevirapine in patients on rifampicin.59 This strategy
was used in a randomized, controlled trial conducted
in Mozambique that compared starting efavirenz
versus nevirapine-based HAART in patients on
rifampicin-based TB treatment. With a starting
dosage of 200 mg twice daily, those in the nevirapine
arm still experienced poorer virological outcomes
compared with the efavirenz arm (60% vs. 68.4% viral
load suppression <50 copies/mL at 48 weeks, respec-
tively).63 Therewas no excess of drug adverse events in
the nevirapine arm despite starting at 200 mg twice
daily in contrast with a previous small Thai study that
raised safety concerns in relation to omitting the
lead-in dose.61 Thus, wherever possible nevirapine
should not be started in patients on rifampicin. If
nevirapine has to be used because of efavirenz una-
vailability, then we suggest omitting the nevirapine
lead-in dose and starting at 200 mg bd.
In healthy volunteer studies and early patient
studies, it was observed that rifampicin caused mod-
erate reductions in plasma concentrations of efa-
virenz.64 However, when studied in HIV-infected
patients on treatment for TB in Africa and Asia, no
significant reduction in efavirenz concentrations
were demonstrated.65,66 In some African patients, efa-
virenz concentrations may actually increase on TB
treatment.67 A 29.5% reduction of efavirenz clearance
was reported, which could be explained by cyto-
chrome P450 polymorphisms.68 Similar results have
also been reported in Asian populations where poly-
morphisms in the cytochrome P450 2B6 isoenzyme
and haplotypes are known to result in wide interindi-
vidual variations.69 While certain national guidelines
suggest increasing efavirenz to 800 mg daily with
rifampicin in those with higher body weight,70 this is
not recommended in the World Health Organization
guidelines.71 Recent study results have shown no dif-
ference in the proportion with an efavirenz trough
concentration <1 mg/L when comparing between
patients on rifampicin and efavirenz 600 mg daily
who have body weight <50 kg and >50 kg.72 A large
cohort study in South Africa showed that the propor-
tion of patients achieving HIV virological suppression
was similar among those on efavirenz-based HAART
regimen (at 600 mg dose) while on rifampicin-based
TB treatment or otherwise.62 The effects of rifampicin
on efavirenz appear to be time-dependent as reported
in one study with a difference at week 4 but not at
week 16.73 As regards the newer non-nucleoside
reverse transcriptase inhibitor, there are substantial
interactions between etravirine and rifampicin, and
they should not be co-administered.74
PI and rifampicin
The concentrations of antiretrovirals in the PI class
are very substantially reduced when co-administered
with rifampicin. Cmin of PI decreases by 80–95%
when co-administered with rifampicin resulting in
subtherapeutic concentrations and virological break-
through at standard doses.75 This can be overcome in
the case of lopinavir/ritonavir by increasing doses to
800 mg/200 mg bd (i.e. double dose) or 400 mg/
400 mg bd.76 In studies of HIV-infected TB patients in
Africa, the 800 mg/200 mg strategy was reasonably
well tolerated with favourable virological outcome,
apart from gastrointestinal side-effects, although
these studies have been small.77,78 It is advisable to
Table 2 Shared side-effects of antiretroviral and anti-mycobacterials in the management of TB/HIV co-infections
Side-effects Antiretrovirals Anti-mycobacterials
Nausea AZT, ddI, PI Pyrazinamide, ethionamide
Hepatitis NVP, EFV, PI (NRTI can
cause steatohepatitis)
Rifampicin, isoniazid, pyrazinamide and many second line
drugs including quinolones
Peripheral neuropathy D4T, ddI Isoniazid, ethionamide, terizidone/cycloserine
Renal impairment TDF Aminoglycosides
Rash NVP, EFV Rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin
and many second line drugs including quinolones
Neuropsychiatric EFV Terizidone/cycloserine, quinolones, isoniazid
AZT, zidovudine; D4T, stavudine; ddI, didanosine; EFV, efavirenz; HIV, human immunodeficiency virus; NRTIs, nucleoside reverse
transcriptase inhibitors; NVP, nevirapine; PI, protease inhibitor; TB, tuberculosis; TDF, tenofovir.
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monitor liver function tests (or at least ALT levels) in
patients on rifampicin and increased doses of
lopinavir/ritonavir.
Integrase inhibitors and rifampicin
Rifampicin induces the glucuronidation (via
UGT1A1) of integrase inhibitors. Trough concentra-
tions of raltegravir are decreased by over 50% by con-
comitant use of rifampicin.79 US prescribing
information advises that the dose of raltegravir be
doubled when given with rifampicin (from 400 mg bd
to 800 mg bd). A recent study, however, demonstrated
that virological suppression at 24 weeks was similar
with standard compared with double-dose raltegravir
both combined with rifampicin.80 However, this study
was relatively small, and there was a trend towards
more HIV resistance emerging in the 400 mg bd arm.
In healthy subjects, dolutegravir level appears not to
be significantly reduced by rifampicin when using a
50 mg bd dose compared with 50 mg daily in the
absence of rifampicin.81
Rifabutin as an alternative
In contrast with rifampicin, rifabutin has far less effect
on antiretroviral metabolism. It is advised in devel-
opedworld guidelines that rifabutin be substituted for
rifampicin in patients on PI-based HAART.70 In most
resource-limited settings, however, the high cost of
rifabutin often makes it unavailable for treatment. As
rifampicin is usually given infixeddose combinations,
a single drug switch to rifabutin, even if available,
would be operationally complex to implement.59
Rifabutin is safe, effective andmaybe cost-savingwith
PI-based regimens, and further research and consid-
eration of a rifabutin fixed dose combination are war-
ranted. Rifabutin given at 150 mg alternate days with
either lopinavir/ritonavir or darunavir/ritonnavir at
standard doses does not significantly reduce exposure
to lopinavir or darunavir, respectively. PI, however, do
inhibit the metabolism of rifabutin,59 and it is advised
that the dose of rifabutin be reduced and dosing fre-
quency decreased to reduce risks of rifabutin toxicity.
Dosing schedules suggested include 150 mg three
times per week, 150 mg alternate days and 150 mg
daily. Concerns have been raised that the intermittent
dosing regimens may result in subtherapeutic rifabu-
tin concentrations and potential rifamycin resistance.
The optimal rifabutin dose that achieves adequate
concentrations with minimal toxicity has not been
definitively determined.Therapeutic drugmonitoring
is advised, but this is impractical in resource-limited
settings.70,71
DIAGNOSIS AND TREATMENT OF
LATENT TB INFECTION IN HIV/AIDS
Direct identification of individuals who are latently
infected with live MTB without active disease is not
possible. Current immunodiagnostic tests ascertain a
state of persistent MTB-specific immune responses
rather than true latent infection.82 Conventionally
latent TB infection is diagnosed by a positive TST, as
defined by an induration size of 5 mm or more in the
HIV-infected, after ruling out active disease. Despite
possible limitations in sensitivity and specificity, TST
remains a useful primary screening test for the diag-
nosis of latent TB infection among HIV-infected
persons, with up to 24-fold difference in risk of subse-
quent active TB disease between test-positive and
test-negative subjects in a previous study.83 Newer
blood tests (interferon-g release assays) based on
T-cell response toMTB–specific antigens arenot influ-
enced by previous BCG vaccination and have several
operational advantages, for example no return visit
required, operator independence and no boosting
effect from repeated testing.82 While data on the
disease-predicting values of interferon-g release
assays among HIV-infected persons remain scanty, a
meta-analysis suggested rather similar performance
betweenTST and interferon-g release assay, at least in
low- and intermediate-income countries.84 Currently
available data on the efficacy of preventive treatment
in HIV-infected patients are primarily based on
TST. Notwithstanding these gaps in existing data,
interferon-g release assays are gaining increasing
acceptance in high-income countries, particularly for
screening of BCG-vaccinated subjects and as com-
pared withTST, their sensitivitymight also be affected
to a lesser extent in patients with compromised
immunity.82
Given that HIV-positive individuals with latent TB
are at increased risk for development of active TB,
isoniazid prophylaxis has been advocated in the pre-
vention of active disease. In a recent meta-analysis
including seven trialswith 4316HIV-infected subjects,
treatment with either 6 or 12 months of daily or inter-
mittent isoniazid significantly reduced the risk of TB
(relative risk 0.36) in individuals with a positive
TST.85 Pyridoxine (10–50 mg per day) is generally
co-administered to reduce the risk of adverse events,
especially peripheral neuropathy.82,85 The optimal
duration of isoniazid for the prevention of TB in HIV-
infected individuals, however, remainsunclear.82,85 Ina
systematic review of 13 studies, there was no signifi-
cant increase in risk (summary relative risk 1.45, 95%
confidence interval 0.85–2.47) for the emergence of
bacillary resistance between the isoniazid arms and
the placebo/no treatment arms.86 Results were similar
when studies of non-HIV infected and HIV-infected
persons were considered separately. Because of
incomplete testing and small numbersof resistant iso-
lates, however, a modest increase in risk could not be
excluded.There is insufficient evidence for theprotec-
tive efficacy of preventive treatment among HIV-
infected subjects with a negative latent TB test.85
Because of the intrinsic limitations of existing immu-
nodiagnostic tests among severely immunocompro-
mised individuals,82,85 exceptional consideration
might still be made for initiation of preventive treat-
ment among anergic HIV-infected subjects in the
presenceof significant recentTBexposure (e.g. house-
hold contacts). On the other hand, primary prophy-
laxis against TB in HIV-exposed children has not been
found to be effective.87
Long-term follow-up studies suggested that the
protection of 6–12 months of isoniazid treatment in
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HIV-infected persons could be short-lasting (1–2.5
years).88,89 Reinfection after completion of isoniazid
preventive therapy could have contributed to such
observation as both studies were conducted in areas
with high incidence of TB. In a recent clinical trial in
Botswana, 36 months of treatment with isoniazid
was significantly more effective than 6 months
among HIV patients with a positive TST of 5 mm
induration (hazard ratio 0.26, P = 0.02) but not in
those with a negative test (0·75, P = 0.40), suggesting
continuing risk of reactivation or reinfection after 6
months of treatment.90 The added protective effect
of continuous isoniazid (36 months) was however
not confirmed in another clinical trial on an
intention-to-treat analysis.91 Increased rates of
adverse effects and treatment termination might
have accounted for the different observations, as
post-hoc analysis suggested that continuous isoni-
azid did have a protective effect while the patients
were taking the drugs.91
Isoniazid plus rifampicin has also been found to
significantly reduce the TB risk (relative risk 0.41;
confidence interval 0.21–0.81) and death (relative
risk 0.69; confidence interval 0.50–0.95) among HIV-
infected individuals.85 Equivalent efficacy was
observed between isoniazid for 6–12 months and
isoniazid plus rifampicin for 3 months, but adverse
events leading to treatment termination were more
frequent among those receiving isoniazid/rifampicin
combination although this was not statistically sig-
nificant. Rifapentine 900 mg plus isoniazid 900 mg
weekly for 12 weeks has recently been shown to be
equally effective as 6 months of isoniazid among
HIV-infected subjects.91 Despite the early enthusi-
asm on rifampicin plus pyrazinamide for 2 months,
the regimen is seldom used today because of fre-
quent adverse events, especially increased incidence
of hepatotoxicity among non-HIV-infected individu-
als.82,85 No randomized, controlled trial has been
published on the use of rifampicin alone in pre-
dominantly HIV-infected persons perhaps because
of concern for acquired rifampicin resistance.82,85
There are extremely scanty data from clinical trials
or observational studies to inform decision and the
choice of regimen for preventive treatment of HIV-
infected close contacts of individual with multidrug-
resistant TB.
CONCLUSIONS
Diagnosis and management of TB/HIV co-infection
present a clinical challenge in intermediate and high
TB burden countries. While the principles of early
diagnosis, prompt treatment and effective prevention
(of activeTB disease) are well-known, there is a lack of
practicable algorithms for application at specific time
points in the course of the co-infections. Consider-
able advances have been made in the last decade
through a synthesis of results from observational
studies and clinical trials, addressing the optimal
timing for HAART initiation, pharmacological strate-
gies, detection and treatment of TB-IRIS. However
optimal diagnosis and management of latent TB
remain a challenge and need to be tailored to the epi-
demiological characteristics at country levels. Finally,
molecular diagnosis has contributed to clinical diag-
nosis but is feasible only if it is widely accessible and
affordable.
Acknowledgements
SSL thanks Li Ka Shing Institute of Health Sciences and Stanley
Ho Centre for Emerging Infectious Diseases for technical
support. GM receives support from the Wellcome Trust
(098316). AK receives funding support from the Ministry of
Higher Education Malaysia, High Impact Research Grant
(HIRGA E000001-20001).
REFERENCES
1 Centers for Disease Control and Prevention (CDC). CDC Grand
Rounds: the TB/HIV syndemic. MMWR Morb. Mortal.Wkly Rep.
2012; 61: 484–9.
2 World Health Organization. Global Tuberculosis Report 2012.
WHO, Geneva, 2012.
3 Global Report:UNAIDSReport on the Global AIDS Epidemic 2012.
UNAIDS, Geneva, 2012.
4 Getahun H, Gunneberg C, Granich R et al. HIV infection-
associated tuberculosis: the epidemiology and the response.
Clin. Infect. Dis. 2010; 50(Suppl. 3): S201–7.
5 Martinson NA, Hoffmann CJ, Chaisson RE. Epidemiology of
tuberculosis and HIV: recent advances in understanding and
responses. Proc. Am. Thorac. Soc. 2011; 8: 288–93.
6 Kassa A, Teka A, Shewaamare A et al. Incidence of tuberculosis
and early mortality in a large cohort of HIV infected patients
receiving antiretroviral therapy in a tertiary hospital in Addis
Ababa, Ethiopia. Trans. R. Soc. Trop.Med. Hyg. 2012; 106: 363–70.
7 Jiang X, Lu H, Zhang Y et al. A cross-sectional study of HIV and
tuberculosis coinfection cases in mainland China. South.Med. J.
2008; 101: 914–7.
8 Choun K, Thai S, Pe R et al. Incidence and risk factors for tuber-
culosis inHIV-infected patients while on antiretroviral treatment
in Cambodia. Trans. R. Soc. Trop. Med. Hyg. 2013; 107: 235–42.
9 Stuckler D, Basu S, McKee M et al. Mining and risk of tuberculo-
sis in sub-Saharan Africa. Am. J. Public Health 2011; 101: 524–30.
10 Velasco M, Castilla V, Cervero M et al. The changing pattern of
tuberculosis and HIV co-infection in immigrants and Spaniards
in the last 20 years. HIV Med. 2008; 9: 227–33.
11 Raghavan S, Alagarasu K, Selvaraj P. Immunogenetics of HIV and
HIV associated tuberculosis. Tuberculosis (Edinb.) 2012; 92:
18–30.
12 Braun MM, Truman BI, Maguire B et al. Increasing incidence of
tuberculosis in a prison inmate population. AssociationwithHIV
infection. JAMA 1989; 261: 393–7.
13 Moges B, Amare B, Asfaw F et al. Prevalence of smear positive
pulmonary tuberculosis among prisoners in North Gondar Zone
Prison, northwest Ethiopia. BMC Infect. Dis. 2012; 12: 352.
14 Rutta E, Mutasingwa D, Ngallaba S et al. Tuberculosis in a prison
population inMwanza,Tanzania (1994–1997). Int. J. Tuberc. Lung
Dis. 2001; 5: 703–6.
15 Nyangulu DS, Harries AD, Kang’ombe C et al. Tuberculosis in a
prison population in Malawi. Lancet 1997; 350: 1284–7.
16 Kittikraisak W, Burapat C, Kaewsa-ard S et al. Factors associated
with tuberculosis treatment default among HIV-infected tuber-
culosis patients in Thailand. Trans. R. Soc. Trop. Med. Hyg. 2009;
103: 59–66.
17 Tseng SH, Jiang DD, Hoi HS et al. Impact of HAART therapy on
co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
Am. J. Trop. Med. Hyg. 2009; 80: 675–7.
18 Miranda A, Morgan M, Jamal L et al. Impact of antiretroviral
therapy on the incidence of tuberculosis: the Brazilian experi-
ence, 1995–2001. PLoS ONE 2007; 2: e826.
SS Lee et al.920
© 2013 The Authors
Respirology © 2013 Asian Pacific Society of Respirology
Respirology (2013) 18, 912–922
19 Suthar AB, Lawn SD, del Amo J et al. Antiretroviral therapy for
prevention of tuberculosis in adults with HIV: a systematic
review and meta-analysis. PLoS Med. 2012; 9: e1001270.
20 Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and
multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis.
2007; 196(Suppl. 1): S86–107.
21 Dubrovina I, Miskinis K, Lyepshina S et al. Drug-resistant tuber-
culosis and HIV in Ukraine: a threatening convergence of two
epidemics? Int. J. Tuberc. Lung Dis. 2008; 12: 756–62.
22 Ritacco V, López B, Ambroggi M et al. HIV infection and geo-
graphically bound transmission of drug-resistant tuberculosis,
Argentina. Emerg. Infect. Dis. 2012; 18: 1802–10.
23 Sergeev R, Colijn C, Murray M et al. Modeling the dynamic rela-
tionship betweenHIV and the risk of drug-resistant tuberculosis.
Sci Transl Med 2012; 4: 135ra67.
24 Dye C, Williams BG, Espinal MA et al. Erasing the world’s slow
stain: strategies to beat multidrug-resistant tuberculosis. Science
2002; 295: 2042–6.
25 Schutz C, Meintjes G, Almajid F et al. Clinical management of
tuberculosis andHIV-1 co-infection.Eur.Respir. J. 2010; 36: 1460–
81.
26 Chan CK, Alvarez Bognar F, Wong KH et al. The epidemiology
and clinical manifestations of human immunodeficiency virus-
associated tuberculosis in Hong Kong. Hong Kong Med. J. 2010;
16: 192–8.
27 Naing C, Mak JW, Maung M et al. Meta-analysis: the association
between HIV infection and extrapulmonary tuberculosis. Lung
2013; 191: 27–34.
28 Department of HIV/AIDS, Stop TB Department, World Health
Organization. Guidelines for Intensified Tuberculosis Case-
Finding and Isoniazid Preventive Therapy for People Living with
HIV in Resource-Constrained Settings. WHO, Geneva, 2011.
29 Department of HIV/AIDS, Stop TB Department, World Health
Organization. Improving the Diagnosis and Treatment of Smear-
Negative Pulmonary and Extrapulmonary Tuberculosis among
Adults and Adolescents. Recommendations for HIV-Prevalent and
Resource-Constrained Settings. WHO, Geneva, 2007.
30 Getahun H, Harrington M, O’Brien R et al. Diagnosis of smear-
negative pulmonary tuberculosis in people with HIV infection or
AIDS in resource-constrained settings: informing urgent policy
changes. Lancet 2007; 369: 2042–9.
31 Corbett EL, Zezai A, Cheung YB et al. Provider-initiated symptom
screening for tuberculosis in Zimbabwe: diagnostic value and
the effect of HIV status. Bull.World Health Organ. 2010; 88: 13–
21.
32 Hanifa Y, Fielding KL, Charalambous S et al. Tuberculosis among
adults starting antiretroviral therapy in South Africa: the need for
routine case finding. Int. J. Tuberc. Lung Dis. 2012; 16: 1252–9.
33 Ho TT, Wong KH, Lee SS. Low yield of chest radiography in
screening for active pulmonary tuberculosis in HIV-infected
patients in Hong Kong. Int. J. STD AIDS 1999; 10: 409–12.
34 Getahun H, Kittikraisak W, Heilig CM et al. Development of a
standardized screening rule for tuberculosis in people livingwith
HIV in resource-constrained settings: individual participant data
meta-analysis of observational studies. PLoS Med. 2011; 8:
e1000391.
35 Scott LE, McCarthy K, Gous N et al. Comparison of Xpert MTB/
RIF with other nucleic acid technologies for diagnosing pulmo-
nary tuberculosis in a high HIV prevalence setting: a prospective
study. PLoS Med. 2011; 8: e1001061.
36 Lawn SD, Brooks SV, Kranzer K et al. Screening for HIV-
associated tuberculosis and rifampicin resistance before antiret-
roviral therapy using the Xpert MTB/RIF assay: a prospective
study. PLoS Med. 2011; 8: e1001067.
37 Lawn SD, Kerkhoff AD, Vogt M et al. High diagnostic yield of
tuberculosis from screening urine samples from HIV-infected
patients with advanced immunodeficiency using the Xpert
MTB/RIF assay. J. Acquir. Immune Defic. Syndr. 2012; 60: 289–94.
38 Peter JG, Theron G, Muchinga TE et al. The diagnostic accuracy
of urine-based Xpert MTB/RIF in HIV-infected hospitalized
patients who are smear-negative or sputum scarce. PLoS ONE
2012; 7: e39966.
39 Abimbola TO, Marston BJ, Date AA et al. Cost-effectiveness of
tuberculosis diagnostic strategies to reduce early mortality
among persons with advanced HIV infection initiating antiretro-
viral therapy. J. Acquir. Immune Defic. Syndr. 2012; 60: e1–7.
40 Andrews JR, Lawn SD, Rusu C et al. The cost-effectiveness of
routine tuberculosis screening with Xpert MTB/RIF prior to ini-
tiation of antiretroviral therapy: a model-based analysis. AIDS
2012; 26: 987–95.
41 Narita M, Ashkin D, Hollender ES et al. Paradoxical worsening of
tuberculosis following antiretroviral therapy in patients with
AIDS. Am. J. Respir. Crit. Care Med. 1998; 158: 157–61.
42 Tadokera R, Meintjes G, Skolimowska KH et al. Hypercytokinae-
mia accompanies HIV-tuberculosis immune reconstitution
inflammatory syndrome. Eur. Respir. J. 2011; 37: 1248–59.
43 Marais S, Meintjes G, Pepper DJ et al. Frequency, severity, and
prediction of tuberculous meningitis immune reconstitution
inflammatory syndrome. Clin. Infect. Dis. 2013; 56: 450–60.
44 MüllerM,Wandel S, Colebunders R et al. Immune reconstitution
inflammatory syndrome in patients starting antiretroviral
therapy forHIV infection: a systematic review andmeta-analysis.
Lancet Infect. Dis. 2010; 10: 251–61.
45 Barr DA, Ramdial PK. Clinicopathological correlates in HIV sero-
positive tuberculosis cases presenting with jaundice after initi-
ating antiretroviral therapy with a structured review of the
literature. BMC Infect. Dis. 2012; 12: 257.
46 PepperDJ,Marais S,MaartensG et al. Neurologicmanifestations
of paradoxical tuberculosis-associated immune reconstitution
inflammatory syndrome: a case series. Clin. Infect. Dis. 2009; 48:
e96–107.
47 Lawn SD, Myer L, Bekker LG et al. Tuberculosis-associated
immune reconstitution disease: incidence, risk factors and
impact in an antiretroviral treatment service in South Africa.
AIDS 2007; 21: 335–41.
48 BurmanW, Weis S, Vernon A et al. Frequency, severity and dura-
tion of immune reconstitution events in HIV-related tuberculo-
sis. Int. J. Tuberc. Lung Dis. 2007; 11: 1282–9.
49 Breton G, Bourgarit A, Pavy S et al. Treatment for tuberculosis-
associated immune reconstitution inflammatory syndrome
in 34 HIV-infected patients. Int. J. Tuberc. Lung Dis. 2012; 16:
1365–70.
50 Huyst V, Lynen L, Bottieau E et al. Immune reconstitution
inflammatory syndrome in an HIV/TB co-infected patient four
years after starting antiretroviral therapy. Acta Clin. Belg. 2007;
62: 126–9.
51 Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated
immune reconstitution inflammatory syndrome: case defini-
tions for use in resource-limited settings. Lancet Infect.Dis. 2008;
8: 516–23.
52 Meintjes G, Wilkinson RJ, Morroni C et al. Randomized placebo-
controlled trial of prednisone for paradoxical tuberculosis-
associated immune reconstitution inflammatory syndrome.
AIDS 2010; 24: 2381–90.
53 Blanc FX, Sok T, Laureillard D et al. Earlier versus later start of
antiretroviral therapy in HIV-infected adults with tuberculosis.
N. Engl. J. Med. 2011; 365: 1471–81.
54 Havlir DV, Kendall MA, Ive P et al. Timing of antiretroviral
therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med.
2011; 365: 1482–91.
55 Naidoo K, Yende-Zuma N, Padayatchi N et al. The immune
reconstitution inflammatory syndrome after antiretroviral
therapy initiation in patients with tuberculosis: findings from the
SAPiT trial. Ann. Intern. Med. 2012; 157: 313–24.
56 Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation
of antiretroviral drugs during tuberculosis therapy. N. Engl. J.
Med. 2010; 362: 697–706.
57 Manosuthi W, Mankatitham W, Lueangniyomkul A et al. Time
to initiate antiretroviral therapy between 4 weeks and 12 weeks
of tuberculosis treatment in HIV-infected patients: results from
TB/HIV co-infection 921
© 2013 The Authors
Respirology © 2013 Asian Pacific Society of Respirology
Respirology (2013) 18, 912–922
the TIME study. J. Acquir. Immune Defic. Syndr. 2012; 60: 377–
83.
58 Török ME, Yen NT, Chau TT et al. Timing of initiation of antiret-
roviral therapy in human immunodeficiency virus (HIV)—
associated tuberculous meningitis. Clin. Infect. Dis. 2011; 52:
1374–83.
59 Maartens G, Decloedt E, Cohen K. Effectiveness and safety of
antiretrovirals with rifampicin: crucial issues for high-burden
countries. Antivir. Ther. 2009; 14: 1039–43.
60 van Oosterhout JJ, Kumwenda JJ, Beadsworth M et al.
Nevirapine-based antiretroviral therapy started early in the
course of tuberculosis treatment in adult Malawians. Antivir.
Ther. 2007; 12: 515–21.
61 Avihingsanon A, Manosuthi W, Kantipong P et al. Pharmacoki-
netics and 48-week efficacy of nevirapine: 400 mg versus 600 mg
per day in HIV-tuberculosis coinfection receiving rifampicin.
Antivir. Ther. 2008; 13: 529–36.
62 Boulle A, Van Cutsem G, Cohen K et al. Outcomes of nevirapine-
and efavirenz-based antiretroviral therapy when coadministered
with rifampicin-based antitubercular therapy. JAMA 2008; 300:
530–9.
63 Bonnet M, Bhatt N, Baudin E et al. Results of the CARINEMO-
ANRS 12 146 randomized trial comparing the efficacy and safety
of nevirapine versus efavirenz for treatment of HIV-TB
co-infected patients in Mozambique. 6th International AIDS
Society Conference, 2011, Rome, Italy. Abstract WELBX05.
64 López-Cortés LF, Ruiz-Valderas R, Viciana P et al. Pharmacoki-
netic interactions between efavirenz and rifampicin in HIV-
infected patients with tuberculosis. Clin. Pharmacokinet. 2002;
41: 681–90.
65 Cohen K, Grant A, Dandara C et al. Effect of rifampicin-based
antitubercular therapy and the cytochrome P450 2B6 516G>T
polymorphism on efavirenz concentrations in adults in South
Africa. Antivir. Ther. 2009; 14: 687–95.
66 Ramachandran G, Hemanth Kumar AK, Rajasekaran S et al.
CYP2B6 G516T polymorphism but not rifampin coadministra-
tion influences steady-state pharmacokinetics of efavirenz in
human immunodeficiency virus-infected patients in South
India. Antimicrob. Agents Chemother. 2009; 53: 863–8.
67 Kwara A, Lartey M, Sagoe KW et al. Paradoxically elevated efa-
virenz concentrations in HIV/tuberculosis-coinfected patients
with CYP2B6 516TT genotype on rifampin-containing antituber-
culous therapy. AIDS 2011; 25: 388–90.
68 Gengiah TN, Holford NH, Botha JH et al. The influence of tuber-
culosis treatment on efavirenz clearance in patients co-infected
with HIV and tuberculosis. Eur. J. Clin. Pharmacol. 2012; 68: 689–
95.
69 Manosuthi W, Sukasem C, Lueangniyomkul A et al. Impact of
Pharmacogenetic markers of CYP2B6, clinical factors, and
drug-drug interaction on efavirenz concentrations in HIV/
tuberculosis-coinfected patients. Antimicrob. Agents Chemother.
2013; 57: 1019–24.
70 Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the use of antiretroviral agents in HIV-1-infected
adults and adolescents. Department of Health and Human Serv-
ices. 2013. [Accessed 18 February 2013.] Available from URL:
http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
71 World Health Orgainsation. Antiretroviral Therapy for HIV Infec-
tion in Adults and Adolescents: Recommendations for A Public
Health Approach—2010 Revision. WHO, Geneva, 2010. [Accessed
18 February 2013.] Available fromURL: http://www.who.int/hiv/
pub/arv/adult2010/en/index.html
72 Borand L, Laureillard D, Madec Y et al. Plasma concentrations of
efavirenz with a 600 mg standard dose in Cambodian HIV-
infected adults treated for tuberculosis with a body weight above
50 kg. Antivir. Ther. 2013; 18: 419–23.
73 Ngaimisi E, Mugusi S, Minzi O et al. Effect of rifampicin and
CYP2B6 genotype on long-term efavirenz autoinduction and
plasma exposure in HIV patients with or without tuberculosis.
Clin. Pharmacol. Ther. 2011; 90: 406–13.
74 Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacoki-
netic interactions between etravirine and non-antiretroviral
drugs. Clin. Pharmacokinet. 2011; 50: 25–39.
75 L’homme RF, Nijland HM, Gras L et al. Clinical experience with
the combined use of lopinavir/ritonavir and rifampicin. AIDS
2009; 23: 863–5.
76 la Porte CJ, Colbers EP, Bertz R et al. Pharmacokinetics of
adjusted-dose lopinavir-ritonavir combined with rifampin
in healthy volunteers. Pharmacokinetics of adjusted-dose
lopinavir-ritonavir combined with rifampin in healthy volun-
teers. Antimicrob. Agents Chemother. 2004; 48: 1553–60.
77 Murphy RA, Marconi VC, Gandhi RT et al. Coadministration
of lopinavir/ritonavir and rifampicin in HIV and tuberculosis
co-infected adults in South Africa. PLoS ONE 2012; 7: e44793.
78 Decloedt EH, Maartens G, Smith P et al. The safety, effectiveness
and concentrations of adjusted lopinavir/ritonavir in HIV-
infected adults on rifampicin-based antitubercular therapy.
PLoS ONE 2012; 7: e32173.
79 Wenning LA, HanleyWD, Brainard DM et al. Effect of rifampin, a
potent inducer of drug-metabolizing enzymes, on the pharma-
cokinetics of raltegravir. Antimicrob. Agents Chemother. 2009; 53:
2852–6.
80 Grinsztejn B, Castro ND, Arnold V et al. A randomized multicen-
tre open-label trial to estimate the efficacy and safety of two
doses of raltegravir (RAL) to efavirenz (EFV) for the treatment of
HIV-TB co-infected patients: results of the ANRS 12 180 Reflate
TB trial. 19th International AIDS Conference, 2012, Washington
DC, USA. Abstract THLBB01.
81 Dooley KE, Sayre P, Borland J et al. Safety, tolerability, and phar-
macokinetics of the HIV integrase inhibitor dolutegravir given
twice daily with rifampin or once daily with rifabutin: results of a
phase 1 study among healthy subjects. J. Acquir. Immune Defic.
Syndr. 2013; 62: 21–7.
82 Leung CC, Rieder HL, Lange C et al. Treatment of latent infection
with Mycobacterium tuberculosis: update 2010. Eur. Respir. J.
2011; 37: 690–711.
83 Selwyn PA, Hartel D, Lewis VA et al. A prospective study of the
risk of tuberculosis among intravenous drug users with human
immunodeficiency virus infection. N. Engl. J. Med. 1989; 320:
545–50.
84 Rangaka MX, Wilkinson KA, Glynn JR et al. Predictive value of
interferon-g release assays for incident active tuberculosis: a sys-
tematic review and meta-analysis. Lancet Infect. Dis. 2012; 12:
45–55.
85 Akolo C, Adetifa I, Shepperd S et al. Treatment of latent tubercu-
losis infection in HIV infected persons. Cochrane Database Syst.
Rev. 2010; (1): CD000171.
86 Balcells ME, Thomas SL, Godfrey-Faussett P et al. Isoniazid pre-
ventive therapy and risk for resistant tuberculosis. Emerg. Infect.
Dis. 2006; 12: 744–51.
87 Madhi SA, Nachman S, Violari A et al. Primary isoniazid prophy-
laxis against tuberculosis in HIV-exposed children. N. Engl. J.
Med. 2011; 365: 21–31.
88 Johnson JL, Okwera A, Hom DL et al. Duration of efficacy of
treatment of latent tuberculosis infection in HIV-infected adults.
AIDS 2001; 15: 2137–47.
89 Quigley MA, Mwinga A, Hosp M et al. Long-term effect of pre-
ventive therapy for tuberculosis in a cohort of HIV-infected
Zambian adults. AIDS 2001; 15: 215–22.
90 Samandari T, Agizew TB, Nyirenda S et al. 6-month versus
36-month isoniazid preventive treatment for tuberculosis in
adults with HIV infection in Botswana: a randomised, double-
blind, placebo-controlled trial. Lancet 2011; 377: 1588–98.
91 Martinson NA, Barnes GL, Moulton LH et al. New regimens to
prevent tuberculosis in adults with HIV infection.N. Engl. J.Med.
2011; 365: 11–20.
SS Lee et al.922
© 2013 The Authors
Respirology © 2013 Asian Pacific Society of Respirology
Respirology (2013) 18, 912–922
